TP53 and neoplasm: Nutlin-3a showed robust inhibition of p53-MDM2 binding in vitro and tumor suppression with p53 upregulation in vivo, and served as a prototype in developing next-generation MDM2 inhibitors that are currently being tested in clinical trials [85].